SANTARUS INC (SNTS) Downgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research downgraded shares of SANTARUS INC (SNTS) from OUTPERFORM to NEUTRAL on August 14, 2012, with a target price of $8.00.

Santarus Inc is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary products for the prevention and treatment of gastrointestinal diseases and disorders.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on SANTARUS INC (SNTS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply